Flavonoids as modulators of metabolic enzymes and drug transporters

Flavonoids, natural compounds found in plants and in plant‐derived foods and beverages, have been extensively studied with regard to their capacity to modulate metabolic enzymes and drug transporters. In vitro , flavonoids predominantly inhibit the major phase I drug‐metabolizing enzyme CYP450 3A4 and the enzymes responsible for the bioactivation of procarcinogens (CYP1 enzymes) and upregulate the enzymes involved in carcinogen detoxification (UDP‐glucuronosyltransferases, glutathione S ‐transferases (GSTs)). Flavonoids have been reported to inhibit ATP‐binding cassette (ABC) transporters (multidrug resistance (MDR)–associated proteins, breast cancer–resistance protein) that contribute to the development of MDR. P‐glycoprotein, an ABC transporter that limits drug bioavailability and also induces MDR, was differently modulated by flavonoids. Flavonoids and their phase II metabolites (sulfates, glucuronides) inhibit organic anion transporters involved in the tubular uptake of nephrotoxic compounds. In vivo studies have partially confirmed in vitro findings, suggesting that the mechanisms underlying the modulatory effects of flavonoids are complex and difficult to predict in vivo . Data summarized in this review strongly support the view that flavonoids are promising candidates for the enhancement of oral drug bioavailability, chemoprevention, and reversal of MDR.